MA33768B1 - Triazolopyridines - Google Patents
TriazolopyridinesInfo
- Publication number
- MA33768B1 MA33768B1 MA34899A MA34899A MA33768B1 MA 33768 B1 MA33768 B1 MA 33768B1 MA 34899 A MA34899 A MA 34899A MA 34899 A MA34899 A MA 34899A MA 33768 B1 MA33768 B1 MA 33768B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- preparation
- formula
- ttk
- monopolar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS TRIAZOLOPYRIDINES REPRÉSENTÉS PAR LA FORMULE GÉNÉRALE (I) QUI SONT DES INHIBITEURS DE LA KINASE DE FUSEAU MONOPOLAIRE 1 (MPS-1 OU TTK) : FORMULE (I), DANS LAQUELLE R1, R2, R3, R4 ET R5 SONT TELS QUE DONNÉS DANS LA DESCRIPTION ET LA REVENDICATION. L'INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS ET DES COMBINAISONS PHARMACEUTIQUES QUI COMPORTENT LESDITS COMPOSÉS, L'UTILISATION DESDITS COMPOSÉS POUR LA FABRICATION D'UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT OU LA PROPHYLAXIE DE MALADIES PROLIFÉRATIVES, AINSI QUE DES COMPOSÉS INTERMÉDIAIRES UTILES DANS LA PRÉPARATION DESDITS COMPOSÉS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075535A EP2343297A1 (fr) | 2009-11-30 | 2009-11-30 | Triazolopyridines |
| PCT/EP2010/006994 WO2011063908A1 (fr) | 2009-11-30 | 2010-11-17 | Triazolopyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33768B1 true MA33768B1 (fr) | 2012-11-01 |
Family
ID=42028156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34899A MA33768B1 (fr) | 2009-11-30 | 2012-05-28 | Triazolopyridines |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9676766B2 (fr) |
| EP (2) | EP2343297A1 (fr) |
| JP (1) | JP5805653B2 (fr) |
| KR (1) | KR20120115290A (fr) |
| CN (1) | CN102762557B (fr) |
| AR (1) | AR079166A1 (fr) |
| AU (1) | AU2010324155B2 (fr) |
| BR (1) | BR112012012906A2 (fr) |
| CA (1) | CA2781915A1 (fr) |
| CL (1) | CL2012001391A1 (fr) |
| CR (1) | CR20120295A (fr) |
| CU (1) | CU24100B1 (fr) |
| CY (1) | CY1115866T1 (fr) |
| DK (1) | DK2507235T3 (fr) |
| DO (1) | DOP2012000150A (fr) |
| EA (1) | EA022353B1 (fr) |
| EC (1) | ECSP12011935A (fr) |
| ES (1) | ES2525069T3 (fr) |
| GT (1) | GT201200165A (fr) |
| HN (1) | HN2012001162A (fr) |
| HR (1) | HRP20141093T1 (fr) |
| IL (1) | IL219750A (fr) |
| MA (1) | MA33768B1 (fr) |
| MX (1) | MX2012006252A (fr) |
| MY (1) | MY160325A (fr) |
| NZ (1) | NZ600229A (fr) |
| PE (1) | PE20121509A1 (fr) |
| PH (1) | PH12012501055A1 (fr) |
| PL (1) | PL2507235T3 (fr) |
| PT (1) | PT2507235E (fr) |
| RS (1) | RS53670B1 (fr) |
| SI (1) | SI2507235T1 (fr) |
| TN (1) | TN2012000265A1 (fr) |
| UA (1) | UA108486C2 (fr) |
| WO (1) | WO2011063908A1 (fr) |
| ZA (1) | ZA201203806B (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343294A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines substituées |
| EP2343297A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9284317B2 (en) | 2010-12-17 | 2016-03-15 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors |
| WO2012080228A1 (fr) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines 6-thio substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération |
| US20140187548A1 (en) | 2010-12-17 | 2014-07-03 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CA2821829A1 (fr) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Imidazopyrazines pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation |
| WO2012080232A1 (fr) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines 2-substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération |
| US20140135319A1 (en) | 2010-12-17 | 2014-05-15 | Bayer Intellectual Property Gmbh | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CA2831710A1 (fr) | 2011-03-31 | 2012-10-04 | Bayer Intellectual Property Gmbh | Benzimidazoles substitues servant d'inhibiteurs de mps-1 kinase |
| US20140255392A1 (en) | 2011-04-06 | 2014-09-11 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and intermediates thereof |
| US20140120087A1 (en) * | 2011-04-21 | 2014-05-01 | Bayer Intellectual Property Gmbh | Triazolopyridines |
| WO2012160029A1 (fr) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Triazolopyridines substituées |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| JP6166289B2 (ja) | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾピリダジン |
| CN104603136B (zh) * | 2012-07-10 | 2017-06-27 | 拜耳医药股份有限公司 | 制备取代的三唑并吡啶的方法 |
| WO2014020043A1 (fr) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinaisons pour le traitement du cancer |
| WO2014020041A1 (fr) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinaisons pour le traitement du cancer |
| EP2951174B1 (fr) | 2013-01-30 | 2017-04-26 | Bayer Pharma Aktiengesellschaft | Isothiazoles amino-substitués |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| CA2914516A1 (fr) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Triazolopyridines substituees |
| JP2016520665A (ja) | 2013-06-11 | 2016-07-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ |
| CA2914745A1 (fr) * | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Derives de type promedicament de triazolopyridines substituees |
| EP2980088A1 (fr) | 2014-07-28 | 2016-02-03 | Bayer Pharma Aktiengesellschaft | Isothiazoles substitués d'amine |
| CA2944610C (fr) | 2014-04-07 | 2024-01-09 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indozilines |
| EP2977375A1 (fr) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Isoxazoles substitués par amino |
| EP2977377A1 (fr) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Isoxazoles substitués par amino |
| EP2977376A1 (fr) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Isoxazoles substitués par amino |
| EP3283642B1 (fr) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Biomarqueurs pronostiques pour chimiothérapie basée sur un inhibiteur de ttk |
| KR101686411B1 (ko) * | 2015-12-28 | 2016-12-14 | 한국원자력의학원 | 피리딘계 유도체를 포함하는 암 예방 또는 치료용 조성물 |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| JP7023217B2 (ja) | 2017-12-01 | 2022-02-21 | ダイキン工業株式会社 | アルカリ接触する表面を有する構成要素 |
| WO2020097396A1 (fr) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Dérivés de benzimidazole et dérivés d'aza-benzimidazole en tant qu'inhibiteurs de janus kinase 2 et leurs utilisations |
| EP3876939A4 (fr) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations |
| US12509455B2 (en) * | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| CA3156828A1 (fr) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase tricycliques et leurs utilisations |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267574B1 (fr) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-hétéroaryloxy benzimidazoles et azabenzimidazoles utilisés en tant qu'inhibiteurs de jak2 |
| WO2022178340A2 (fr) * | 2021-02-22 | 2022-08-25 | Orgenesis Inc. | Compositions pharmaceutiques comprenant de la ranpirnase |
| CA3234638A1 (fr) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| JP4499721B2 (ja) | 2003-06-30 | 2010-07-07 | ヒフ バイオ,インク. | 化合物、組成物および方法 |
| EP1799680A2 (fr) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Derives de triazolopyridine comme agents antibacteriens |
| WO2007065010A2 (fr) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Composes anti-angiogenese |
| HRP20100378T1 (hr) | 2006-05-31 | 2010-08-31 | Galapagos N.V. | Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| CN101801966A (zh) * | 2007-07-18 | 2010-08-11 | 诺瓦提斯公司 | 双环杂芳基化合物和它们作为激酶抑制剂的用途 |
| EP2212326A1 (fr) * | 2007-08-23 | 2010-08-04 | AstraZeneca AB | 2-anilinopurin-8-ones utilisees comme inhibiteurs de ttk/mps1 pour le traitement de dereglements proliferatifs |
| CA2691448A1 (fr) * | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Composes de triazolopyridine et leur utilisation comme inhibiteurs de ask |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| UA102828C2 (en) | 2007-11-27 | 2013-08-27 | Целльзом Лимитед | Amino triazoles as p13k inhibitors |
| WO2010092015A1 (fr) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Dérivés d'urée-triazolo[1,5-a]pyridine en tant qu'inhibiteurs de pi3k |
| EP2396324A1 (fr) * | 2009-02-13 | 2011-12-21 | Fovea Pharmaceuticals | Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines servant d'inhibiteurs de kinases |
| JP6168773B2 (ja) | 2009-04-29 | 2017-07-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾキノキサリン |
| WO2011026579A1 (fr) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Aminoquinoxalines substituées servant d'inhibiteurs de tyrosine-thréonine kinases |
| EP2343294A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines substituées |
| EP2343297A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Dérivés de triazolopyridine |
| PH12012501381A1 (en) | 2010-01-15 | 2012-10-22 | Janssen Pharmaceuticals Inc | Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
-
2009
- 2009-11-30 EP EP09075535A patent/EP2343297A1/fr not_active Withdrawn
-
2010
- 2010-11-17 JP JP2012541336A patent/JP5805653B2/ja not_active Expired - Fee Related
- 2010-11-17 MY MYPI2012002378A patent/MY160325A/en unknown
- 2010-11-17 PE PE2012000742A patent/PE20121509A1/es not_active Application Discontinuation
- 2010-11-17 KR KR1020127016940A patent/KR20120115290A/ko not_active Ceased
- 2010-11-17 PL PL10787274T patent/PL2507235T3/pl unknown
- 2010-11-17 CA CA2781915A patent/CA2781915A1/fr not_active Abandoned
- 2010-11-17 AU AU2010324155A patent/AU2010324155B2/en not_active Ceased
- 2010-11-17 UA UAA201207609A patent/UA108486C2/uk unknown
- 2010-11-17 HR HRP20141093AT patent/HRP20141093T1/hr unknown
- 2010-11-17 BR BR112012012906A patent/BR112012012906A2/pt not_active IP Right Cessation
- 2010-11-17 SI SI201030810T patent/SI2507235T1/sl unknown
- 2010-11-17 RS RS20140646A patent/RS53670B1/sr unknown
- 2010-11-17 CN CN201080061524.1A patent/CN102762557B/zh not_active Expired - Fee Related
- 2010-11-17 MX MX2012006252A patent/MX2012006252A/es active IP Right Grant
- 2010-11-17 CU CU2012000084A patent/CU24100B1/es active IP Right Grant
- 2010-11-17 PH PH1/2012/501055A patent/PH12012501055A1/en unknown
- 2010-11-17 ES ES10787274.9T patent/ES2525069T3/es active Active
- 2010-11-17 WO PCT/EP2010/006994 patent/WO2011063908A1/fr not_active Ceased
- 2010-11-17 EA EA201200794A patent/EA022353B1/ru not_active IP Right Cessation
- 2010-11-17 DK DK10787274.9T patent/DK2507235T3/en active
- 2010-11-17 US US13/512,701 patent/US9676766B2/en not_active Expired - Fee Related
- 2010-11-17 PT PT107872749T patent/PT2507235E/pt unknown
- 2010-11-17 EP EP10787274.9A patent/EP2507235B1/fr active Active
- 2010-11-17 NZ NZ600229A patent/NZ600229A/en not_active IP Right Cessation
- 2010-11-30 AR ARP100104406A patent/AR079166A1/es unknown
-
2012
- 2012-05-13 IL IL219750A patent/IL219750A/en not_active IP Right Cessation
- 2012-05-24 ZA ZA2012/03806A patent/ZA201203806B/en unknown
- 2012-05-25 TN TNP2012000265A patent/TN2012000265A1/en unknown
- 2012-05-28 MA MA34899A patent/MA33768B1/fr unknown
- 2012-05-30 CR CR20120295A patent/CR20120295A/es unknown
- 2012-05-30 DO DO2012000150A patent/DOP2012000150A/es unknown
- 2012-05-30 EC ECSP12011935 patent/ECSP12011935A/es unknown
- 2012-05-30 GT GT201200165A patent/GT201200165A/es unknown
- 2012-05-30 HN HN2012001162A patent/HN2012001162A/es unknown
- 2012-05-30 CL CL2012001391A patent/CL2012001391A1/es unknown
-
2014
- 2014-11-21 CY CY20141100970T patent/CY1115866T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34308B1 (fr) | Triazolopyridines substituées | |
| MA35826B1 (fr) | Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk | |
| MA40523A (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| MA47447B1 (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA37798B1 (fr) | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes | |
| MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
| MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
| MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA35444B1 (fr) | Ligands du récepteur ep1 | |
| MA32468B1 (fr) | Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k | |
| MA37891B1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
| PH12012501055A1 (en) | Triazolopyridines | |
| MA34067B1 (fr) | Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA31863B1 (fr) | Dérivés de pyrazole comme inhibiteurs de 5-lo | |
| MA34806B1 (fr) | Compositions pharmaceutiques | |
| MA34917B1 (fr) | Dérivés substitués de l'acide 3-hétéroaroylamino-propionique et leur utilisation comme composés pharmaceutiques | |
| MA42988B1 (fr) | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide | |
| MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
| MA35102B1 (fr) | Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2 |